Supernus Pharmaceuticals Inc (SUPN)

Financial leverage ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Total assets	US$ in thousands	1,368,070	1,342,700	1,315,830	1,304,090	1,277,670	1,285,160	1,293,100	1,791,810	1,702,510	1,693,130	1,694,970	1,639,520	1,689,150	1,555,040	1,573,060	1,507,440	1,504,100	1,510,020	1,491,020	1,189,870
Total stockholders’ equity	US$ in thousands	1,035,730	1,007,150	957,454	929,166	921,516	912,191	919,908	912,150	886,204	852,798	841,434	828,446	815,851	810,468	785,579	754,444	744,858	708,879	665,974	613,383
Financial leverage ratio		1.32	1.33	1.37	1.40	1.39	1.41	1.41	1.96	1.92	1.99	2.01	1.98	2.07	1.92	2.00	2.00	2.02	2.13	2.24	1.94

December 31, 2024 calculation

Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $1,368,070K ÷ $1,035,730K
= 1.32

The financial leverage ratio of Supernus Pharmaceuticals Inc has fluctuated over the past few years, ranging from a high of 2.24 in June 2020 to a low of 1.32 in December 2024. This ratio measures the company's level of debt relative to its equity, indicating the extent to which the company relies on debt financing.

A higher financial leverage ratio suggests that the company is more heavily reliant on debt to fund its operations and investments, which can increase financial risk. On the other hand, a lower ratio indicates a healthier balance between debt and equity, reducing the risk of financial distress.

The trend in Supernus Pharmaceuticals Inc's financial leverage ratio shows some variability, with periods of increase followed by decreases. It is important for investors and analysts to closely monitor this ratio as it can provide insights into the company's capital structure and financial health.